Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

Pharmacies currently making copycat versions of Eli Lilly’s tirzepatide face heightened exposure to state enforcement actions ...

She could go to a med-spa, but that would cost about $1,000 a month, still too much for the new therapist. Then ... it became ...

And please do keep in touch. … European Union antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings’ ...

Kentucky, Alaska and Alabama are the three states where weight loss drugs are most used ... claims for the drugs rapidly increased after the U.S. Food and Drug Administration (FDA) approved the ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...

Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...

The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...

Online health platforms continue to advertise access to copycat versions of blockbuster weight-loss drugs Wegovy and Zepbound ...

Lizzo has taken a rather silly reference to her on a recent “South Park” episode and elevated it to a hilarious Halloween ...